PEPTONIC Medical AB (publ) INTERIM REPORT january – march 2023 (www.spotlightstockmarket.com, ticker: PMED)
· Significantly improved results · Continuous very positive development in core business Medical Consumer · Improved results but declining sales in business unit Lifestyle Consumer GROUP 2022 FIRST QUARTER (jan-mar) · Net sales of products SEK 8 874 (8 908) thousand · Gross profit SEK 4 869 (5 596) thousand, 55% (63%) · Operating loss SEK -6 654 (-10 875) thousand · Loss per share -0,008 (-0,059) SEKWord from our CEO It is with great joy we can report that the positive development of the core business, clinically proven intimate self-care products,